Objective: To determine pregnant women's preferences for the treatment of insomnia: cognitive behavioral therapy (CBT-I), pharmacotherapy, or acupuncture.
Participants:
The sample (N ¼ 187) was primarily White (70%), married or common-law married (96%), and on average 31 years of age; the mean gestational age was 28 weeks.
Methods: Participants read expert-validated descriptions of CBT-I, pharmacotherapy, and acupuncture and then indicated their preferences and perceptions of each approach.
Results: Participants indicated that if they experienced insomnia, they preferred CBT-I to other approaches, c 2 (2) ¼ 38.10, p < .001. They rated CBT-I as the most credible treatment (h 2 partial ¼ .22, p < .001) and had stronger positive reactions to it than to the other two approaches (h 2 partial ¼ .37, p < .001). Conclusion: Participants preferred CBT-I for insomnia during pregnancy. This preference is similar to previously reported preferences for psychotherapy for treatment of depression and anxiety during pregnancy. It is important for clinicians to consider women's preferences when discussing possible treatment for insomnia. JOGNN, 46, e95-e104; 2017 . http://dx.doi.org/10.1016/j.jogn.2017.01.005
Accepted January 2017 P atient preferences are increasingly recognized as key factors in the delivery of evidence-based care (Charles, Gafni, & Whelan, 1999; Tompkins, Swift, & Callahan, 2013) . The delivery of preferred treatments for psychological problems, including mood and sleep disorders, has been shown to improve adherence and outcomes (Lin et al., 2005; Vincent & Lionberg, 2001) . A growing number of researchers suggest that women prefer nonpharmacologic therapies for the treatment of mood and anxiety disorders during pregnancy (Arch, 2014; Dimidjian & Goodman, 2014; Goodman, Dimidjian, & Williams, 2013) . Although it follows that they may also prefer nonpharmacologic interventions for the treatment of insomnia in pregnancy, to our knowledge, no articles have been published to date on this question.
The lack of evidence about treatment preferences for insomnia in pregnancy is important, because sleep complaints are common among pregnant women (Baratte-Beebe & Lee, 1999; Facco, Kramer, Ho, Zee, & Grobman, 2010; Hutchison et al., 2012; Lee, Zaffke, & McEnany, 2000) . Subthreshold symptoms of insomnia measured by the Insomnia Severity Index are frequent across all trimesters of pregnancy and were reported by 57% (Mindell, Cook, & Nikolovski, 2015) to 74% (Ferná ndez-Alonso, Trabaló nPastor, Chedraui, & Pé rez-Ló pez, 2012) of participants. Clinically significant symptoms were reported by 14% (Mindell et al., 2015) to 27% (Fernández-Alonso et al., 2012) of participants. Moreover, symptoms of insomnia increase as pregnancy progresses, with risk estimated as 2.03 times greater in the third trimester than in the first trimester (Kızılırmak, Timur, & Kartal, 2012) . After childbirth, subjective sleep quality was stable in most participants; those with poor sleep quality in pregnancy continued to report poor sleep quality in the postpartum period (Tomfohr, Buliga, Letourneau, Campbell, & Giesbrecht, 2015) .
Disturbed sleep is associated with a number of potential maternal consequences. For example, poorer sleep quality in early pregnancy predicted greater levels of depression symptoms later in pregnancy and in the postpartum period (Skouteris, Wertheim, Germano, Paxton, & Milgrom, 2009; Tomfohr et al., 2015) . Poorer sleep quality and shorter sleep duration during pregnancy were also associated with greater risk of preterm labor, longer labor, and increased risk of cesarean birth (Lee & Gay, 2004; Okun, Schetter, & Glynn, 2011) . Clearly, disturbed sleep in pregnant women is an important concern for the health of mother and child, and a number of treatment modalities (psychotherapy, pharmacotherapy, and complementary alternative treatments) are available from which to choose.
Potential Treatments for Insomnia in Pregnancy
Among psychotherapeutic treatments, cognitive behavioral therapy for insomnia (CBT-I) is a nonpharmacologic, evidence-based treatment that combines elements of cognitive (e.g., challenging maladaptive beliefs about sleep) and behavioral (e.g., sleep restriction) therapy to treat insomnia. In a number of clinical trials, researchers indicated that CBT-I was effective to reduce symptoms of insomnia, and benefits continued for as long as 3 years posttreatment (Backhaus, Hohagen, Voderholzer, & Riemann, 2001; Edinger, Wohlgemuth, Radtke, Marsh, & Quillian, 2001; Morin, Colecchi, & Stone, 1999; Morin, Kowatch, Barry, & Walton, 1993) . In contrast, discontinuation of medication for sleep is often associated with a return of insomnia symptoms (Riemann & Perlis, 2009) . The authors of a small pilot study tested CBT-I in pregnancy and found it to be effective to reduce symptoms of insomnia (Tomfohr-Madsen, Clayborne, Rouleau, & Campbell, 2016) . CBT-I also was effective to reduce symptoms of insomnia during the postpartum period (Swanson, Flynn, Adams-Mundy, Armitage, & Arnedt, 2013) . Overall, CBT-I appears to be a promising treatment for insomnia during the perinatal period; however, large-scale efficacy trials are needed.
Several different classes of hypnotic medications are available to treat insomnia. Although these medications are effective in the short term, they are also accompanied by safety concerns when used during pregnancy. These drug classes include benzodiazepine receptor agonists, antidepressants, and g-aminobutyric acid reuptake inhibitors (Feren, Katyal, & Walsh, 2006) . In terms of safety of sleep medications for the treatment of insomnia in the prenatal period, some authors suggested that benzodiazepine and hypnotic benzodiazepine receptor agonists are associated with increased risk of preterm labor, low birth weight, and small-for-gestational-age infants (Okun, Ebert, & Saini, 2015) . In particular, zolpidem, a g-aminobutyric acid agonist medication, has been associated with preterm birth, cesarean birth, and low-birth-weight infants (Juric, Newport, Ritchie, Galanti, & Stowe, 2009; Wang, Lin, Lin, & Chen, 2010) . With regard to efficacy, the sleeping medications trazodone (an antidepressant medication) and diphenhydramine (an antihistamine) improved total sleep time and sleep efficiency in pregnant women (Khazaie, Ghadami, Knight, Emamian, & Tahmasian, 2013) . Khazaie et al. also reported that pharmacologic treatment of insomnia in pregnancy was associated with decreased symptoms of postpartum depression compared with placebo. Overall, more research is needed on the balance between efficacy and safety of various pharmacologic agents for treatment of insomnia during the prenatal period.
Complementary and alternative medicine treatments are also available. Researchers found that many women use such interventions during pregnancy, in part because of a greater perception of control over health and well-being (Hall, Griffiths, & McKenna, 2011; Warriner, Bryan, & Brown, 2014) . Acupuncture is a commonly used treatment with some preliminary evidence to support its efficacy in the treatment of insomnia (Cheuk, Yeung, Chung, & Wong, 2012) . Authors of one small trial on acupuncture for treatment of insomnia during pregnancy reported that pregnant women were more likely to experience a greater than 50% reduction in symptoms if they received acupuncture plus sleep hygiene education compared with sleep hygiene education alone (da Silva & Nakamura, 2005) . Results from this study indicate that acupuncture may be an efficacious treatment for insomnia experienced during pregnancy, although randomized controlled clinical trials are needed.
Currently, little is known about women's treatment preferences for insomnia during pregnancy or the factors that may influence these preferences.
Previous researchers found a relationship between psychological variables, such as past depressive symptoms, and treatment preferences. Pregnant women with histories of depression expressed more positive reactions to pharmacotherapy than those without histories of depression (Dimidjian & Goodman, 2014) . Greater scores on the Edinburgh Postnatal Depression Scale (EPDS) were associated with more negative perceptions of individual counseling and antidepressant use when breastfeeding (Goodman, 2009) . Expectant mothers showed a preference for psychotherapy compared with pharmacotherapy for treatment of anxiety (Arch, 2014) . Most participants indicated a preference for individual therapy over medication or group therapy (Goodman, 2009) . We built on this line of research and considered the relationship between severity of insomnia, depression, and anxiety symptoms and preferences for treatment of insomnia during pregnancy. We also examined whether women's perceptions of the effectiveness and credibility of a treatment were associated with treatment choice.
We had three aims in our study. First, we wanted to determine what treatment modality expectant mothers would select as the preferred treatment for insomnia. Based on the extant literature, we hypothesized that more expectant mothers would select CBT-I than pharmacotherapy. Second, we aimed to determine which of the three treatments expectant mothers would perceive as the most credible and effective. Our hypothesis was that CBT-I would receive greater credibility and personal reaction ratings than pharmacotherapy and acupuncture. Our third aim was to determine what factors are associated with the treatment choice of expectant mothers. We made no hypotheses regarding this aim.
Methods
The study was a cross-sectional survey of women during pregnancy. We recruited participants in person between October 2014 and March 2015 from waiting rooms in low-risk maternity clinics and at a pregnancy and infant trade show in Calgary, Alberta, Canada. The inclusion criteria included pregnancy and ability to read and write in English. The project was approved by the Institutional Review Board at the University of Calgary.
Procedures
After we recruited participants, we obtained informed consent. We gave participants the choice to receive the questionnaire via e-mail to be completed at home or to fill it out in person on an iPad (Apple, Cupertino, CA) provided by the researcher. Next, participants read through each of the treatment descriptions, rated the credibility of each, and indicated their personal reactions to each. Finally, participants filled out a demographics form and several sleep and mood questionnaires. At the end of the survey, each participant received a $10 gift card. We gave participants the option to withdraw from the survey halfway through and still receive a $5 gift card.
Materials
We drafted descriptions of each treatment that were reviewed by an expert in the field of that intervention, including specialists in clinical psychology, a medical doctor who specialized in obstetrics, and a traditional Chinese medicine specialist. The experts read through their respective descriptions and provided suggestions that would ensure that the treatment was described as accurately as possible. These descriptions are available in Supplemental Table S1 .
Each description was designed to answer the following questions: What is the approach? How does the approach conceptualize insomnia? How does the approach work? What will I do in this approach? How much time is involved? What are the risks? The questions and descriptions were adapted from previous research regarding treatment preferences (Dimidjian & Goodman, 2014; Goodman et al., 2013) . All three descriptions were equivalent in length and were presented in random order to control for potential biases created by the serial position effect (Troyer, 2011) .
Measures
Credibility Scale. We used the Credibility Scale to capture how credible and effective the participants perceived each described treatment to be. This scale was adapted slightly from one used in depression research (Addis & Carpenter, 1999) , and the word insomnia was used in place of depression. The scale consisted of seven 7-point Likert scale items(1 ¼ not at all, 7 ¼ extremely) on the extent to which each approach was perceived to be logical, complete, scientific, effective, and Participants preferred cognitive behavioral therapy for insomnia during pregnancy and believed it was the most credible of the three proposed treatments. Personal Reactions to Rationale (PRR). The PRR, which consisted of five 7-point Likert scale items (1 ¼ not at all to 7 ¼ extremely), allowed participants to indicate how helpful they thought each approach would be to themselves, to what extent the approach would help them understand the causes of and learn to cope with insomnia, how likely they were to choose the approach, and how effective they thought the approach would be to treat insomnia. The PRR was adapted slightly from a scale used in previous research (Addis & Carpenter, 1999 Insomnia Severity Index (ISI). We administered the ISI to measure subjective symptoms of insomnia and the degree of impairment or distress caused by the symptoms. The ISI includes seven items with which to assess the severity of sleep-onset and sleep maintenance difficulties, satisfaction with current sleep, daytime impairments, and degree of distress or concern caused by the sleep problems (Bastien, Valliè res, & Morin, 2001 ). Each item is rated on a scale of 0 (none or very satisfied) to 4 (very severe or very dissatisfied) with a total score range of 0 to 28. As scores increase, so do the frequency and severity of insomnia symptoms. In a recent study on the psychometric properties of the ISI, Morin, Bellville, Bé langer, and Ivers (2011) found that a cut score of 10 yielded 86.1% sensitivity and 87.7% specificity for detection of insomnia in a community sample; scores on the ISI also correlated positively with fatigue, anxiety, and depression. Bastien et al. (2001) concluded that the ISI is a reliable and valid instrument to quantify perceived insomnia severity. Consistency reliability in our sample for this measure was .86.
Edinburgh Postnatal Depression Scale. We used the EPDS to measure symptoms of depression in pregnant women. The instrument consists of 10 items rated on a Likert scale from 0 (no, not all) to 3 (yes, all of the time). Greater scores represent greater frequency of symptoms. The EPDS was validated for use during pregnancy with an optimal cut score of 13; sensitivity was estimated at 86%, and specificity was estimated at 78%, with a positive predictive value of 73% (Cox, Holden, & Sagovsky, 1987) . In a study to validate the EPDS against research diagnostic criteria, researchers found good psychometric properties in postnatal and nonpostnatal samples of mothers (Cox, Chapman, Murray, & Jones, 1996) . Cronbach's alpha estimate of internal consistency reliability for our sample was .86.
Pregnancy-Related Anxiety Scale (PRAS).
We used the PRAS to measure pregnancy-related anxiety among participants, particularly the extent to which they were worried about their own
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health, the health of their newborns, and the responsibility of caring for their newborns. The scale consisted of 10 items rated on a Likert scale from 1 (never or not at all) to 4 (a lot of the time or very much; Rini, Dunkel-Schetter, Wadhwa, & Sandman, 1999). Greater scores indicated greater frequency of worry. Rini, Dunkel-Schetter, Wadhwa, and Sandman (1999) found that the PRAS had a positive correlation (r ¼ 0.42) with state anxiety in a sample of pregnant women. The factor structure of the PRAS shows that the scores may be best represented by a single factor, and the use of a total continuous score is acceptable. Cronbach's alpha estimate of internal consistency reliability for our sample was .79.
Statistical Analyses
To determine which treatment participants selected most frequently, we examined the frequency of each treatment choice and conducted a chi-square goodness-of-fit test to assess whether the differences in frequency of treatment selection were significant. To follow up the omnibus chi-square goodness-of-fit test, which included all three treatment choices, we conducted three more chi-square goodness-of-fit tests and compared pairs of treatment choices: CBT-I versus pharmacotherapy, CBT-I versus acupuncture, and acupuncture versus pharmacotherapy.
To determine differences in participants' perceptions of treatment credibility and personal reaction ratings, we conducted a within-subjects analysis of variance to examine whether credibility ratings differed by treatment approach. Next, we conducted a within-subjects analysis of variance to examine if PRR ratings differed by treatment approach. Because there were three conditions in the within-subjects analysis of variance, we tested the assumption of sphericity to confirm that no two conditions were more dependent than another two. We used Mauchly's sphericity test and applied the most conservative correction (lower-bound correction).
Finally, we conducted a multinomial logistic regression to examine which factors determined treatment choice, with treatment choice as the criterion. Treatment credibility ratings; personal reaction ratings; and symptoms of insomnia, depression, and anxiety were predictors. We followed up the omnibus test by examining the discriminative power of predictors between pairs of treatments as described earlier.
Results
In total, 187 women completed the survey; one did not complete the demographics questionnaire, and an additional eight dropped out before they completed the sleep and mood questionnaires. Nine participants declined to report their ages, and four declined to report gestational ages. Most participants were White, employed, and married or common-law married; had median household incomes of CAN$90,000 to $100,000 per year; and were pregnant with their first children. Via three single-item yes/no questions, a number of participants reported that they previously sought help for psychological problems with pharmacotherapy (n ¼ 34, 18%), psychotherapy (n ¼ 38, 20%), and/or complementary alternative treatments (n ¼ 38, 20%; see Table 1 ). Sedov, I. D., Goodman, S. H., and Tomfohr-Madsen, L. M.
Missing Data
We conducted a missing data analysis on all the variables included in the subsequent analyses and found that 3 of the 10 variables had more than 5% missing data. Of the 187 participants, 24 (12.8%) were missing treatment choice data, 12 (6.4%) were missing total EPDS scores, and 14 (7.5%) were missing total ISI scores. Little's missing completely at random test indicated that data were missing completely at random, Table 2 ).
Treatment Perceptions
There were significant differences in credibility ratings among the three interventions, F(1,186) ¼ 52.00, p < .001, h 2 partial ¼ .22. Follow-up tests showed that the mean credibility rating of CBT-I was significantly greater than the mean credibility rating of pharmacotherapy, t (185) Table 2 ).
There were significant differences in personal reaction ratings of the three interventions, F (1,186) Table 2 ).
Determinants of Treatment Choice
We conducted a multinomial logistic regression with treatment choice as the criterion variable and a set of predictors that included credibility and personal reaction ratings of each treatment, insomnia symptoms, depressive symptoms, and pregnancy-related anxiety. Bivariate correlations between the predictors are presented in Table 3 . The model was significantly associated with treatment choice, c 2 (18) ¼ 121.95, p < .001.
Significant predictors within the model included CBT-I credibility ratings, pharmacotherapy personal reaction ratings, and acupuncture personal reaction ratings (see Table 4 ). 
Discussion
Most participants in our study (51%) indicated that they preferred CBT-I as a treatment for insomnia over pharmacotherapy (12%) or acupuncture (37%). Our participants also perceived CBT-I to be the most credible treatment and expected it to be the most effective for them personally. The magnitude of this effect was particularly strong when we investigated differences between credibility (h 2 partial ¼ .38) and personal reaction ratings (h 2 partial ¼ .54) of CBT-I versus pharmacotherapy. Participants' perceptions of the credibility of respective treatments and their personal reactions to rationale underlying the treatment significantly discriminated between treatment choices. Acupuncture was preferred more than pharmacotherapy, but the difference between acupuncture and CBT-I was not statistically significant (p ¼ .065).
Our results are consistent with those of other researchers regarding preferences for treatment of depression and anxiety in pregnancy. Most pregnant women studied preferred psychotherapy to pharmacotherapy (Arch, 2014; Dimidjian & Goodman, 2014; Goodman, 2009; Goodman Sedov, I. D., Goodman, S. H., and Tomfohr-Madsen, L. M. et al., 2013) and may be more receptive to recommendations for psychotherapeutic approaches to insomnia because they perceive them to be more credible and effective during pregnancy. Similar to previous research (Dimidjian & Goodman, 2014) , current depression symptoms in our study were not associated with treatment choice. Additionally, treatment choice was not predicted by current symptoms of insomnia or pregnancy-related anxiety, which indicates that symptom severity is not the driving force behind preference for nonpharmacologic therapy during pregnancy. Treatment credibility and personal reactions were associated with treatment choice, and participants were more likely to select the treatment they perceived to be most credible and effective, which in our sample was CBT-I. Our findings are similar to research on anxiety treatment preferences (Arch, 2014) , in which pregnant women's credibility ratings were strong predictors of willingness to undergo treatment for anxiety.
Our participants may have preferred nonpharmacologic interventions because they were worried about effects on their fetuses. Many pregnant women cite concerns about teratogenicity as an important reason to avoid or discontinue medications, and many consider the consequences of suffering from an illness during pregnancy to be less dangerous for the fetus than taking medication (Lara-Cinisomo, Wisner, Burns, & Chaves-Gnecco, 2014; Lupattelli, Spigset, & Nordeng, 2014; Widnes, Schjøtt, Eide, & Granas, 2013) . LaraCinisomo et al. (2014) found that pregnant Latina women considered pharmacotherapy to be the last resort to treat depression. Conversely, a belief that the benefits of pharmacotherapy outweigh the risks has been shown to correlate with greater medication adherence during pregnancy (Lupattelli et al., 2015) . Pregnant women's perceptions of risk regarding pharmacotherapy use may lead them to select nonpharmacologic approaches before they consider pharmacotherapy.
Implications
Given that perceptions of treatment credibility and effectiveness were related to treatment choice, nurses, physicians, and psychologists who work with pregnant women may wish to discuss evidence that supports the efficacy of various options when they make recommendations for treatment of sleep disruption. Practitioners should also consider that a small but substantial group of pregnant women may prefer pharmacotherapy to other treatment modalities, and they should inquire about these preferences.
Limitations
A number of limitations should be acknowledged when interpreting results from the current study.
We were missing treatment choice data from some participants, although analyses indicated data were missing completely at random. Cronbach's alpha estimate of internal consistency reliability for the PRAS in the current sample was low and may have affected our ability to test the effects of pregnancy-related anxiety on treatment choice. Limited data exist on the content and predictive validity of the credibility and personal reaction scales, and both were adapted from the literature on depression (Addis & Carpenter, 1999; Dimidjian & Goodman, 2014; Goodman et al., 2013) . Most participants reported being of White or Asian descent with high annual household income levels and no confirmed diagnoses of insomnia, which restricted generalizability of the findings. Finally, participants were not asked about prior use of the specific treatments and were not provided with an option for no treatment.
Conclusion
Despite these limitations and constraints on generalization, our findings are in line with other treatment preferences studies and provide strong support for women preferring nonpharmacologic approaches to treat insomnia in pregnancy (da Silva & Nakamura, 2005; Hollenbach, Broker, Herlehy, & Stuber, 2013; Tomfohr-Madsen et al., 2016) . Further study of the efficacy and effectiveness of CBT-I and acupuncture in pregnancy is warranted. Our findings show the importance of treatment preferences in studies of the effects and efficacy of treatments for insomnia in pregnancy. Given the prevalence of sleep disruption during pregnancy and the potential consequences for women and newborns, it is important to develop this area of inquiry and subsequently to disseminate evidence-based treatment guidelines.
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A discussion with a pregnant woman about the efficacy of a recommended treatment may increase the chances that she selects that treatment.
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